2003 International Friedreich's Ataxia Research Conference, 14-16 February 2003, Bethesda, MD, USA

Neuromuscular Disorders

Volumn 14, Issue 1, 2004, Pages 70-82

  Seznec, Hervé ^a   Wilson, Robert B ^b   Puccio, Hélène ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; FRATAXIN; IDEBENONE; IRON SULFUR PROTEIN; PLASMID DNA; UBIDECARENONE;

BIOGENESIS; CARDIOMYOPATHY; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; DISEASE SEVERITY; FRIEDREICH ATAXIA; GENE THERAPY; HEART DILATATION; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; IRON STORAGE; MEDICAL RESEARCH; MITOCHONDRIAL MEMBRANE; MOLECULAR INTERACTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NERVE CELL; SPINOCEREBELLAR TRACT; UNITED STATES;

EID: 0345549506     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2003.10.002     Document Type: Conference Paper

References (40)

1. Harding A.E. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 104:1981;589-620.
2. Campuzano V., Montermini L., Molto M.D., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 271:(5254):1996;1423-1427.
3. Bidichandani S.I., Ashizawa T., Patel P.I. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet. 62:(1):1998;111-121.
4. Koenig M., Mandel J.L. Deciphering the cause of Friedreich ataxia. Curr Opin Neurobiol. 7:(5):1997;689-694.
5. Koenig M. Friedreich ataxia and AVED. Scriver C., Beaudet A., Sly W., Valle D. The metabolic and molecular basis of inherited disease. 2001;5845-5855 MacGraw-Hill, New York.
6. Ohshima K., Montermini L., Wells R.D., Pandolfo M. Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem. 273:(23):1998;14588-14595.
7. Sakamoto N., Chastain P.D., Parniewski P., et al. Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia. Mol Cell. 3:(4):1999;465-475.
8. Sakamoto N., Larson J.E., Iyer R.R., Montermini L., Pandolfo M., Wells R.D. GGA*TCC-interrupted triplets in long GAA*TTC repeats inhibit the formation of triplex and sticky DNA structures, alleviate transcription inhibition, and reduce genetic instabilities. J Biol Chem. 276:(29):2001;27178- 27187.
9. Sakamoto N., Ohshima K., Montermini L., Pandolfo M., Wells R.D. Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem. 276:(29):2001;27171- 27177.
10. Vetcher A.A., Napierala M., Iyer R.R., Chastain P.D., Griffith J.D., Wells R.D. Sticky DNA, a long GAA.GAA.TTC triplex that is formed intramolecularly, in the sequence of intron 1 of the frataxin gene. J Biol Chem. 277:(42):2002;39217-39227.
11. Vetcher A.A., Napierala M., Wells R.D. Sticky DNA: effect of the polypurine.polypyrimidine sequence. J Biol Chem. 277:(42):2002;39228-39234.
12. Saveliev A., Everett C., Sharpe T., Webster Z., Festenstein R. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature. 422:(6934):2003;909-913.
13. Adamec J., Rusnak F., Owen W.G., et al. Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am J Hum Genet. 67:(3):2000;549-562.
14. Park S., Gakh O., Mooney S.M., Isaya G. The ferroxidase activity of yeast frataxin. J Biol Chem. 277:(41):2002;38589-38595.
15. Park S., Gakh O., O'Neill H.A., et al. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J Biol Chem. 278:(33):2003;31340-31351.
16. Gakh O., Adamec J., Gacy A.M., Twesten R.D., Owen W.G., Isaya G. Physical evidence that yeast frataxin is an iron storage protein. Biochemistry. 41:(21):2002;6798-6804.
17. Nichol H., Gakh O., O'Neill H.A., Pickering I.J., Isaya G., George G.N. Structure of frataxin iron cores: an X-ray absorption spectroscopic study. Biochemistry. 42:(20):2003;5971-5976.
18. Lesuisse E., Santos R., Matzanke B.F., Knight S.A., Camadro J.M., Dancis A. Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum Mol Genet. 12:(8):2003;879-889.
19. Becker E., Richardson D.R. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int J Biochem Cell Biol. 33:(1):2001;1-10.
20. Becker E.M., Greer J.M., Ponka P., Richardson D.R. Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood. 99:(10):2002;3813- 3822.
21. Levi S., Corsi B., Bosisio M., et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem. 276:(27):2001;24437-24440.
22. Drysdale J., Arosio P., Invernizzi R., et al. Mitochondrial ferritin: a new player in iron metabolism. Blood Cells Mol Dis. 29:(3):2002;376-383.
23. Corsi B., Cozzi A., Arosio P., et al. Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J Biol Chem. 277:(25):2002;22430-22437.
24. Cazzola M., Invernizzi R., Bergamaschi G., et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood. 101:(5):2003;1996-2000.
25. Muhlenhoff U., Richhardt N., Ristow M., Kispal G., Lill R. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet. 11:(17):2002;2025-2036.
26. Chen O.S., Hemenway S., Kaplan J. Inhibition of Fe-S cluster biosynthesis decreases mitochondrial iron export: evidence that Yfh1p affects Fe-S cluster synthesis. Proc Natl Acad Sci USA. 99:(19):2002;12321-12326.
27. Chen O.S., Hemenway S., Kaplan J. Genetic analysis of iron citrate toxicity in yeast: implications for mammalian iron homeostasis. Proc Natl Acad Sci USA. 99:(26):2002;16922-16927.
28. Miranda C.J., Santos M.M., Ohshima K., et al. Frataxin knockin mouse. Fed Eur Biochem Soc Lett. 512:(1-3):2002;291-297.
29. Pianese L., Busino L., De Biase I., et al. Up-regulation of c-Jun N-terminal kinase pathway in Friedreich's ataxia cells. Hum Mol Genet. 11:(23):2002;2989-2996.
30. Pook M.A., Al-Mahdawi S., Carroll C.J., et al. Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis. Neurogenetics. 3:(4):2001;185-193.
31. Lamarche J.B., Shapcott D., Cote M., Lemieux B. Cardiac iron deposits in Friedreich's ataxia. Lechtenberg R. Handbook of cerebellar diseases. 1993;453-458 Marcel Dekker, New York.
32. Waldvogel D., Gelderen P., Hallett M. Increased iron in the dentate nucleus of patients with Friedreich's ataxia. Ann Neurol. 46:1999;123-125.
33. Rustin P., Rotig A., Munnich A., Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res. 36:(4):2002;467-469.
34. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 60:(10):2003;1676-1679.
35. Murphy M.P. Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction. Expert Opin Biol Ther. 1:(5):2001;753-764.
36. Jauslin M.L., Wirth T., Meier T., Schoumacher F. A cellular model for Friedreich ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet. 11:(24):2002;3055-3063.
37. Richardson D.R., Mouralian C., Ponka P., Becker E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta. 1536:(2-3):2001;133-140.
38. Richardson D.R. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin Investig Drugs. 12:(2):2003;235-245.
39. Lodi R., Hart P.E., Rajagopalan B., et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol. 49:2001;590-596.
40. Musumeci O., Naini A., Slonim A.E., et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 56:(7):2001;849-855.